DDInter1758 DDInter927
Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Telithromycin {u} (Compound) resembles {v} (Compound) Azithromycin
Telithromycin {u} (Compound) binds {v} (Gene) CYP1A2
Telithromycin {u} (Compound) is included by {v} (Pharmacologic Class) Ketolides
Telithromycin {u} (Compound) causes {v} (Side Effect) Bundle branch block
Telithromycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Telithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paricalcitol
Telithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexamethasone
Telithromycin {u} may lead to a major life threatening interaction when taken with {v} Betrixaban
Telithromycin {u} may lead to a major life threatening interaction when taken with {v} Terfenadine
Telithromycin {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Telithromycin (Compound) resembles Azithromycin (Compound)
Telithromycin (Compound) binds CYP1A2 (Gene)
Telithromycin (Compound) is included by Ketolides (Pharmacologic Class)
Telithromycin (Compound) causes Bundle branch block (Side Effect)
Telithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Paricalcitol
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Telithromycin may lead to a major life threatening interaction when taken with Betrixaban
Telithromycin may lead to a major life threatening interaction when taken with Terfenadine
Telithromycin (Compound) resembles Clarithromycin (Compound) and Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin